A new peer-reviewed, open-access feasibility study found that 40 Hz light and sound stimulation delivered in virtual reality was well tolerated, elicited frequency-specific brain responses, and showed acute task-related improvements in memory performance.

SAN FRANCISCO, September 28th, 2026 — Clarity today announced the publication of an early feasibility study of OSMOSIS™, its immersive gamma sensory stimulation platform, in The Journal of Prevention of Alzheimer’s Disease. The findings support Clarity’s development of a non-invasive therapy for Alzheimer’s disease and its broader effort to understand how the brain responds to precisely controlled sensory experiences.

The study enrolled 11 people with mild cognitive impairment due to Alzheimer’s disease or mild cognitive impairment due to Alzheimer's disease. During the session, participants experienced synchronized 40 Hz light and sound stimulation across several virtual reality environments while their brain activity was recorded with EEG. Each participant underwent both active and sham stimulation.

All 11 participants completed the session, with no serious adverse events or discontinuations. Active stimulation produced significantly stronger EEG activity at 40 Hz than baseline and sham stimulation. In exploratory analyses, participants performed better on the study’s associative-memory task for material presented during active stimulation than for material presented during sham stimulation.

“These results show that we can deliver a precise sensory intervention within an engaging experience and measure a corresponding brain response in people with early Alzheimer’s,” said Carolina Reis, PhD, Clarity’s co-founder and Chief Scientific Officer. “The memory findings are very encouraging. Our next milestone is to determine whether repeated use leads to meaningful and sustained cognitive or functional benefits.”

For Clarity, linking a controlled sensory input with a measured brain response and task performance is a first step toward understanding how the brain responds to real-world experiences. Immersive environments let us control what a person sees and hears while measuring neural activity and behavior in context. OSMOSIS™ is built to both intervene and learn: every session pairs a precisely controlled sensory input with the brain’s response and the person’s behavior. Over time, Clarity aims to add further signals and behavioral measures to build richer models of human attention, perception, intent, and response to intervention.

“We’re building a platform that can both intervene and learn,” said Raphael Certain, Clarity’s founder and CEO. “Our near-term goal is an effective, accessible brain therapy that people can use at home. Longer term, we want to generate the multimodal, contextual data needed to understand individual brain responses, personalize interventions, and build better models of human cognition.”

The paper, “Feasibility of Immersive 40 Hz Gamma Sensory Stimulation in Early-stage Alzheimer’s Disease,” was published online on September 25, 2026.

About Clarity

Clarity is developing OSMOSIS™, an immersive platform for non-invasive brain therapy. It combines precisely timed sensory stimulation with interactive experiences and measurement of neural and behavioral responses. Clarity is currently validating the platform in clinical trials, including with patients with Alzheimer’s disease and multiple sclerosis.